With our data interpretation expertise, we can guide pathologists and oncologists to more precise and tailored cancer treatments than ever before. “With technology like Agena’s MassARRAY, clinicians have the ability to develop tests that provide robust data. We are happy to partner with an industry leader like N-of-One to help bring our lab clients an important component that nicely follows the value of our test: an evidence-based, clinically actionable report,” said Pete Dansky, Chief Executive Officer at Agena Bioscience. “MassARRAY Insights is part of Agena Bioscience’s continued effort to support our CLIA-High Complexity Certified lab customers who are tackling the challenges presented in molecular diagnostics. N-of-One’s long standing expertise in clinical interpretation of molecular tests in oncology aids CLIA High Complexity Labs in rapidly delivering actionable, patient-specific treatment options that are supported by the latest scientific and clinical evidence. This strategic partnership supports the expansion of Agena’s recently launched MassARRAY Insights reporting network, which connects the unique capabilities of the MassARRAY with the power of high quality analysis to aid in results interpretation.
The collaboration will focus on results interpretation for cancer genomics.Īgena Bioscience, a global provider of molecular genetic solutions and N-of-One Inc., a leader in molecular decision support for oncology, have teamed together to provide interpretation of cancer genomic data generated by the MassARRAY® System. (Agena Bioscience 201407– CEO before Life Technologies + Applied Biosystems + Arcturus + Affymetrix) "Press Release: Agena Bioscience Bolsters MassARRAY Insights Reporting Network by Adding N-of-One".
Consilium Strategic Communications Annual Healthcare Conference 2022 London.
0 kommentar(er)
